Borroz K I, Buetler T M, Eaton D L
Department of Environmental Health, University of Washington, Seattle 98195.
Toxicol Appl Pharmacol. 1994 May;126(1):150-5. doi: 10.1006/taap.1994.1101.
Dietary 2(3)-tert-butyl-4-hydroxyanisole (BHA) treatment has been shown to increase hepatic glutathione (GSH) content in rats and mice. Subsequent studies in our laboratory have demonstrated that hepatic gamma-glutamylcysteine synthetase (GCS) activity is increased in mice treated with dietary BHA. To test whether this increase in GCS activity follows an increase in hepatic messenger RNA for the large subunit of GCS (GCS-LS mRNA), a 390-base pair fragment corresponding to a region near the 5' end of the rat GCS-LS cDNA sequence was amplified using the PCR reaction and used to detect GCS-LS mRNA on Northern blots. Hepatic GSH, GCS activity, and GCS-LS mRNA levels were determined either in mice treated with BHA in the diet for 12 days or mice injected with diethyl maleate (DEM), phorone, and/or DL-buthionine-[S,R]-sulfoximine (BSO) over a 24 hr period. BHA caused a 1.5-fold increase in GSH levels, a 1.7-fold increase in hepatic GCS activity by Day 12, and a rapid 5-fold increase in hepatic GCS mRNA levels reaching maximal levels after 2-3 days. Partial depletion of GSH with either phorone (70%) or DEM (50%) resulted in a 4- to 5-fold increase in hepatic GCS-LS mRNA levels by 9 hr and a 1.5- to 2-fold increase in hepatic GSH and GCS activity by 24 hr. Depletion of GSH with the GCS enzyme inhibitor BSO had no effect on GCS mRNA expression, even though GSH was depleted to 30%. When BSO was combined with the phorone treatment GSH levels were depleted to < 10%, but the large increase in GCS-LS mRNA seen with phorone alone was greatly attenuated. These data suggest that depletion of GSH per se, is not sufficient to induce elevation of GCS-LS mRNA levels, but that the formation of GSH conjugates may be required to trigger GCS-LS mRNA induction. The increase in GCS-LS mRNA levels may account for the increase in GCS activity and elevation of GSH observed following BHA treatment, as well as the "rebound" of GSH above control levels observed 18-24 hr following depletion of GSH by other chemicals. These results are consistent with the Michael acceptor, hypothesis by Talalay.
饮食中添加2(3)-叔丁基-4-羟基茴香醚(BHA)已被证明可增加大鼠和小鼠肝脏中的谷胱甘肽(GSH)含量。我们实验室随后的研究表明,饮食中添加BHA的小鼠肝脏γ-谷氨酰半胱氨酸合成酶(GCS)活性增加。为了测试GCS活性的增加是否伴随着肝脏中GCS大亚基信使RNA(GCS-LS mRNA)的增加,使用聚合酶链反应(PCR)扩增了与大鼠GCS-LS cDNA序列5'端附近区域相对应的390个碱基对的片段,并用于在Northern印迹上检测GCS-LS mRNA。在饮食中添加BHA处理12天的小鼠或在24小时内注射马来酸二乙酯(DEM)、佛尔酮和/或DL-丁硫氨酸-[S,R]-亚砜胺(BSO)的小鼠中测定肝脏GSH、GCS活性和GCS-LS mRNA水平。BHA使GSH水平增加了1.5倍,到第12天时肝脏GCS活性增加了1.7倍,肝脏GCS mRNA水平迅速增加了5倍,在2 - 3天后达到最高水平。用佛尔酮(70%)或DEM(50%)部分消耗GSH导致肝脏GCS-LS mRNA水平在9小时内增加4至5倍,肝脏GSH和GCS活性在24小时内增加1.5至2倍。用GCS酶抑制剂BSO消耗GSH对GCS mRNA表达没有影响,尽管GSH被消耗到了30%。当BSO与佛尔酮处理联合使用时,GSH水平被消耗到<10%,但单独使用佛尔酮时观察到的GCS-LS mRNA的大幅增加被大大减弱。这些数据表明,GSH本身的消耗不足以诱导GCS-LS mRNA水平升高,但可能需要形成GSH缀合物来触发GCS-LS mRNA的诱导。GCS-LS mRNA水平的增加可能解释了BHA处理后观察到的GCS活性增加和GSH升高,以及其他化学物质消耗GSH后18 - 24小时观察到的GSH高于对照水平的“反弹”。这些结果与Talalay的迈克尔受体假说一致。